Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.33 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL2953336 | 0.86 | MEN1 (0.41) | TSHRCYP2C9PDE4AHTTMEN1 | |
| Cadaverine Tartrate SCHEMBL2962747 | 0.86 | MEN1 (0.41) | TSHRCYP2C9PDE4AHTTMEN1 | |
| SCHEMBL2956370 | 0.85 | HTT (0.41) | GAACYP4F2CYP4A11USP2TSHR | |
| SCHEMBL2962278 | 0.85 | HTT (0.41) | GAACYP4F2CYP4A11USP2TSHR | |
| SCHEMBL2961730 | 0.85 | TSHR (0.33) | USP2TSHRSPHK1SPHK2HTT | |
| Succinic Acid SCHEMBL2961696 | 0.84 | GAA (0.42) | GAACYP4F2CYP4A11USP2TSHR | |
| Malic Acid SCHEMBL2955610 | 0.84 | SMN1; SMN2 (0.46) | GAACYP4F2CYP4A11USP2SPHK1 | |
| Cadaverine Tartrate SCHEMBL2960160 | 0.84 | TSHR (0.39) | TSHRCYP2C9PDE4AHTTMEN1 | |
| SCHEMBL710232 | 0.83 | USP2 (0.42) | GAACYP4F2CYP4A11USP2TSHR | |
| Cadaverine Tartrate SCHEMBL2955530 | 0.83 | GAA (0.38) | GAACYP4F2CYP4A11TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7766978-B2 | Acidic hair dyeing method | KOKYU ALCOHOL KOGYO CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090100609-A1 | ACIDIC HAIR DYE COMPOSITION | KOKYU ALCOHOL KOGYO CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090100609-A1 | ACIDIC HAIR DYE COMPOSITION | H1-0, MRM1, H1-4 | GAA 4480/4885CYP4F2 1673/4885CYP4A11 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.